Disarming CAR-Tregs with a clinical-stage natural product to supercharge CAR-T therapy
Molecular Therapy Oncology · 2026-06 · 34 (2) · 201232
DOI: 10.1016/j.omton.2026.201232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-06. Verfasst von Bowen Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, Shanghai Key Laboratory of Signaling and Disease Research,…. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, Chinese Academy of Sciences Youth Innovation Promotion Association, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized treatment of relapsed/refractory B-cell malignancies, yet about 60% of patients eventually relapse or become resistant.1,2 A key mechanism underlying resistance is the emergence of CAR-expressing regulatory T cells (CAR-Tregs) within infused products. These CAR-Tregs can arise from transduction of natural Tregs or from conventional T cells that acquire a regulatory phenotype upon CAR engagement. Once present, they potently suppress effector CAR-T cells by secreting IL-10 and TGF-β, expressing CTLA-4 and CD25, and metabolically disrupting the tumor microenvironment.
Autor:innen und Institutionen
- Department of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai 2…
Förderung
- Fundamental Research Funds for the Central Universities
- Chinese Academy of Sciences Youth Innovation Promotion Association
- National Natural Science Foundation of China
Zitieren
APA
Li, B., Xu, H., Zhang, W., & Yang, J. (2026). Disarming CAR-Tregs with a clinical-stage natural product to supercharge CAR-T therapy. Molecular Therapy Oncology, 34(2), 201232. https://doi.org/10.1016/j.omton.2026.201232
Vancouver
Li B, Xu H, Zhang W, Yang J. Disarming CAR-Tregs with a clinical-stage natural product to supercharge CAR-T therapy. Molecular Therapy Oncology. 2026;34(2):201232. doi:10.1016/j.omton.2026.201232
BibTeX
@article{Li2026,
author = {Li, Bowen and Xu, Haoran and Zhang, Wenjun and Yang, Jing},
title = {Disarming CAR-Tregs with a clinical-stage natural product to supercharge CAR-T therapy},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {2},
pages = {201232},
doi = {10.1016/j.omton.2026.201232}
}
EUVIMED